{"id":87163,"date":"2026-05-14T12:18:11","date_gmt":"2026-05-14T06:48:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=87163"},"modified":"2026-05-14T12:18:12","modified_gmt":"2026-05-14T06:48:12","slug":"why-is-alembic-pharmaceuticals-share-price-falling-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/","title":{"rendered":"Why Is Alembic Pharmaceuticals Share Price Falling: Key Reasons and Investor Analysis 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>The <strong><a href=\"https:\/\/univest.in\/user\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a> share price falling<\/strong> trend has emerged as a key investor concern in 2026. <strong>Alembic Pharmaceuticals share price falling<\/strong> by approximately 37 percent from its 52 week high of Rs 1,108 to current levels around Rs 700 has raised questions about whether this correction is temporary or reflects deeper pressure. Alembic Pharmaceuticals (NSE: APLLTD), operating in the Generic Pharmaceuticals space, has seen sustained selling pressure since mid 2025. Understanding the <strong>Alembic Pharmaceuticals share price falling<\/strong> dynamic requires a clear look at both company specific headwinds and the broader macroeconomic forces at work. This article covers every key reason behind the <strong>Alembic Pharmaceuticals share price falling<\/strong>, the financial picture, the technical signals, and the recovery catalysts to watch in 2026.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2013 Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#About_Alembic_Pharmaceuticals\" title=\"About Alembic Pharmaceuticals\">About Alembic Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Why_Is_Alembic_Pharmaceuticals_Share_Price_Falling_Key_Reasons\" title=\"Why Is Alembic Pharmaceuticals Share Price Falling: Key Reasons\">Why Is Alembic Pharmaceuticals Share Price Falling: Key Reasons<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#1_Broad_Market_Correction_and_FII_Selling_Pressure\" title=\"1. Broad Market Correction and FII Selling Pressure\">1. Broad Market Correction and FII Selling Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#2_Sector-Specific_Headwinds_in_Generic_Pharmaceuticals\" title=\"2. Sector-Specific Headwinds in Generic Pharmaceuticals\">2. Sector-Specific Headwinds in Generic Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#3_Earnings_Growth_Deceleration_and_Margin_Compression\" title=\"3. Earnings Growth Deceleration and Margin Compression\">3. Earnings Growth Deceleration and Margin Compression<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#4_Valuation_De-Rating_from_Peak_Multiples\" title=\"4. Valuation De-Rating from Peak Multiples\">4. Valuation De-Rating from Peak Multiples<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#5_Small_and_Mid_Cap_Liquidity_Squeeze\" title=\"5. Small and Mid Cap Liquidity Squeeze\">5. Small and Mid Cap Liquidity Squeeze<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#6_Global_Macroeconomic_Uncertainty_and_Tariff_Headwinds\" title=\"6. Global Macroeconomic Uncertainty and Tariff Headwinds\">6. Global Macroeconomic Uncertainty and Tariff Headwinds<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Financial_Performance_Analysis_of_Alembic_Pharmaceuticals\" title=\"Financial Performance Analysis of Alembic Pharmaceuticals\">Financial Performance Analysis of Alembic Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Technical_Signals_What_the_Charts_Are_Saying\" title=\"Technical Signals What the Charts Are Saying\">Technical Signals What the Charts Are Saying<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Can_Alembic_Pharmaceuticals_Share_Price_Recover\" title=\"Can Alembic Pharmaceuticals Share Price Recover\">Can Alembic Pharmaceuticals Share Price Recover<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Why_is_Alembic_Pharmaceuticals_share_price_falling_in_2026\" title=\"Why is Alembic Pharmaceuticals share price falling in 2026?\">Why is Alembic Pharmaceuticals share price falling in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#What_is_the_52_week_high_and_low_of_Alembic_Pharmaceuticals\" title=\"What is the 52 week high and low of Alembic Pharmaceuticals?\">What is the 52 week high and low of Alembic Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#Should_I_buy_Alembic_Pharmaceuticals_shares_at_current_levels\" title=\"Should I buy Alembic Pharmaceuticals shares at current levels?\">Should I buy Alembic Pharmaceuticals shares at current levels?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#What_is_the_latest_news_affecting_Alembic_Pharmaceuticals_stock\" title=\"What is the latest news affecting Alembic Pharmaceuticals stock?\">What is the latest news affecting Alembic Pharmaceuticals stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#What_are_the_recovery_triggers_for_Alembic_Pharmaceuticals\" title=\"What are the recovery triggers for Alembic Pharmaceuticals?\">What are the recovery triggers for Alembic Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/why-is-alembic-pharmaceuticals-share-price-falling-2\/#What_are_the_key_downside_risks_to_Alembic_Pharmaceuticals_stock\" title=\"What are the key downside risks to Alembic Pharmaceuticals stock?\">What are the key downside risks to Alembic Pharmaceuticals stock?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Alembic_Pharmaceuticals\"><\/span><strong>About Alembic Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alembic Pharmaceuticals (NSE: APLLTD) is a listed company in the Generic Pharmaceuticals segment. Vertically integrated pharma company with strong US generics business. 234 ANDA approvals from USFDA. 52W high Rs 1,108. The stock is currently trading at approximately Rs 700, representing a decline of approximately 37 percent from its 52 week high of Rs 1,108. The 52 week low for Alembic Pharmaceuticals is Rs 665. The <strong>Alembic Pharmaceuticals share price falling<\/strong> trend reflects a combination of sector headwinds and company specific pressures that investors need to understand before taking any position decisions.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>APLLTD<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Generic Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td>CMP (April-May 2026)<\/td>\n<td>Rs 700<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,108<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 665<\/td>\n<\/tr>\n<tr>\n<td>Decline from 52W High<\/td>\n<td>Approximately 37 percent<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 13,400 crore (approx)<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>Approximately 23x<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Alembic_Pharmaceuticals_Share_Price_Falling_Key_Reasons\"><\/span><strong>Why Is Alembic Pharmaceuticals Share Price Falling: Key Reasons<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alembic Pharmaceuticals share price falling<\/strong> is being driven by multiple concurrent pressures. Here are the six primary reasons behind the <strong>Alembic Pharmaceuticals share price falling<\/strong> in 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Broad_Market_Correction_and_FII_Selling_Pressure\"><\/span><strong>1. Broad Market Correction and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The dominant external driver behind the <strong>Alembic Pharmaceuticals share price falling<\/strong> is the sustained FII selling wave that swept Indian equities from late 2024 through April 2026. The US reciprocal tariff announcement in April 2026 imposing a 26 percent levy on Indian goods triggered a broad risk off selloff. Alembic Pharmaceuticals fell alongside the broad market correction as institutional investors reduced India allocations. The <strong>Alembic Pharmaceuticals share price falling<\/strong> by 37 percent from its peak reflects the combination of macro-level FII selling and company specific headwinds operating simultaneously in 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Sector-Specific_Headwinds_in_Generic_Pharmaceuticals\"><\/span><strong>2. Sector-Specific Headwinds in Generic Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Beyond the broad market decline, the Generic Pharmaceuticals sector has faced its own challenges in FY26. Analyst earnings estimates for the Generic Pharmaceuticals space have been revised downward across the peer group as input costs, competitive pricing pressures, and demand moderation weighed on the sector outlook. When sector level expectations decline simultaneously, institutional investors reduce overall sector exposure, leading to uniform price declines. The <strong>Alembic Pharmaceuticals share price falling<\/strong> trend is in part a function of this broader sector derating that has continued through early 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Earnings_Growth_Deceleration_and_Margin_Compression\"><\/span><strong>3. Earnings Growth Deceleration and Margin Compression<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A significant company specific driver behind the <strong>Alembic Pharmaceuticals share price falling<\/strong> is the deceleration in earnings growth relative to the elevated expectations priced into the stock at its 52 week high of Rs 1,108. Revenue and profitability metrics have come under pressure from input cost inflation, competitive pricing constraints, and higher operating expenditure. The market, which had priced in sustained growth at the 52 week high, is now recalibrating to a more moderate earnings trajectory. This earnings reset is a core driver of the <strong>Alembic Pharmaceuticals share price falling<\/strong> below analyst targets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Valuation_De-Rating_from_Peak_Multiples\"><\/span><strong>4. Valuation De-Rating from Peak Multiples<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At its 52 week high of Rs 1,108, Alembic Pharmaceuticals was trading at valuations above its historical average. As actual results have come in below peak expectations and sector sentiment has turned cautious, the market has applied lower multiples to Alembic Pharmaceuticals earnings. This valuation de-rating is one of the core mechanisms behind the <strong>Alembic Pharmaceuticals share price falling<\/strong> from Rs 1,108 to the current Rs 700. Multiple compression combined with earnings deceleration explains the full magnitude of the 37 percent correction in the <strong>Alembic Pharmaceuticals share price falling<\/strong> phase.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Small_and_Mid_Cap_Liquidity_Squeeze\"><\/span><strong>5. Small and Mid Cap Liquidity Squeeze<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>With a market capitalisation of approximately Rs 13,400 crore, Alembic Pharmaceuticals is exposed to the liquidity dynamics of the small and mid cap segment, which experienced one of its sharpest liquidity squeezes in FY25-26. When domestic mutual funds face redemption pressure and retail investors turn risk averse, smaller companies bear disproportionate selling pressure. The <strong>Alembic Pharmaceuticals share price falling<\/strong> has been amplified by this small cap liquidity dynamic where thinner order books convert moderate selling into outsized price declines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"6_Global_Macroeconomic_Uncertainty_and_Tariff_Headwinds\"><\/span><strong>6. Global Macroeconomic Uncertainty and Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India\u2019s equity market in FY26 faced an unusually concentrated set of macro headwinds including global tariff wars, crude oil price volatility, currency pressure and concerns about the pace of domestic earnings recovery. The <strong>Alembic Pharmaceuticals share price falling<\/strong> trend has been reinforced by this macro overhang that keeps institutional buyers cautious even when individual company fundamentals do not fully justify the magnitude of the decline. This macro uncertainty is likely to persist until global trade tensions resolve and FII flows return sustainably to Indian equities.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Financial_Performance_Analysis_of_Alembic_Pharmaceuticals\"><\/span><strong>Financial Performance Analysis of Alembic Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The key financial metrics driving the <strong>Alembic Pharmaceuticals share price falling<\/strong> narrative are visible in both recent quarterly trends and the valuation de-rating. The stock has fallen 37 percent from its 52 week high of Rs 1,108 to the current Rs 700, reflecting both earnings pressure and multiple compression. The market cap has contracted to approximately Rs 13,400 crore. Investors tracking the <strong>Alembic Pharmaceuticals share price falling<\/strong> should monitor the upcoming Q4 FY26 results and management commentary on the margin and revenue recovery trajectory as the primary near-term catalyst for any stabilisation.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Key Metric<\/th>\n<th>Current Level<\/th>\n<th>52 Week Peak<\/th>\n<th>Trend<\/th>\n<\/tr>\n<tr>\n<td>Share Price<\/td>\n<td>Rs 700<\/td>\n<td>Rs 1,108<\/td>\n<td>Down 37 percent<\/td>\n<\/tr>\n<tr>\n<td>Market Cap (Rs Cr)<\/td>\n<td>Rs 13,400 crore<\/td>\n<td>Higher at 52W peak<\/td>\n<td>Compressed with price<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>Approximately 23x<\/td>\n<td>Higher at 52W high<\/td>\n<td>Multiple compressed<\/td>\n<\/tr>\n<tr>\n<td>52 Week Range<\/td>\n<td colspan=\"3\">Rs 665 to Rs 1,108<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/univest.in\/screeners\">Screen the best stocks on the Univest Screener.<\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Signals_What_the_Charts_Are_Saying\"><\/span><strong>Technical Signals What the Charts Are Saying<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>On the technical charts, the <strong>Alembic Pharmaceuticals share price falling<\/strong> pattern is confirmed by multiple indicators. The stock is trading at approximately Rs 700, below its 50 day, 100 day, and 200 day simple moving averages, all of which are sloping downward. Since its 52 week high of Rs 1,108, Alembic Pharmaceuticals has formed a clear pattern of lower highs and lower lows. Key support for the <strong>Alembic Pharmaceuticals share price falling<\/strong> trend is at the 52 week low of Rs 665. Overhead resistance is at the Rs 1,108 zone where investors who bought near the peak create selling pressure on any recovery attempt. The RSI has oscillated in oversold territory on multiple occasions during the <strong>Alembic Pharmaceuticals share price falling<\/strong> phase, indicating continued distribution and weak near term buying conviction.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Can_Alembic_Pharmaceuticals_Share_Price_Recover\"><\/span><strong>Can Alembic Pharmaceuticals Share Price Recover<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Despite the headwinds currently driving the <strong>Alembic Pharmaceuticals share price falling<\/strong>, there are genuine recovery catalysts for long term investors to track. First, any positive inflection in the Generic Pharmaceuticals sector driven by improved macro conditions or policy support could trigger a sharp re-rating for Alembic Pharmaceuticals. Second, a quarterly earnings result that beats the now reduced analyst expectations could catalyse a short covering rally from oversold levels. Third, a broad recovery in Indian small and mid cap market sentiment as FII flows normalise post the April 2026 tariff shock would lift Alembic Pharmaceuticals along with the broader peer group.<\/p>\n<p>The contrarian view is that at Rs 700, a significant portion of the bad news driving the <strong>Alembic Pharmaceuticals share price falling<\/strong> is already priced in. The stock is down 37 percent from its peak and the valuation has compressed meaningfully, creating a potentially attractive entry point for patient investors with a 2 to 3 year horizon willing to look through the near term macro uncertainty.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alembic Pharmaceuticals share price falling<\/strong> by approximately 37 percent from its 52 week high of Rs 1,108 to the current Rs 700 reflects a convergence of broad market headwinds, sector pressures in the Generic Pharmaceuticals space, earnings deceleration, FII selling, and valuation de-rating from peak multiples. The <strong>Alembic Pharmaceuticals share price falling<\/strong> trend will require a clear reversal in quarterly financial momentum and improved macro sentiment to arrest sustainably. Investors monitoring the <strong>Alembic Pharmaceuticals share price falling<\/strong> should closely watch upcoming quarterly results, management commentary on growth and margin recovery, and any shifts in FII ownership.<\/p>\n<p><em>This article is for informational purposes only. Please conduct your own research and consult a SEBI registered financial advisor before making any investment decisions. Investment in the share market is subject to market risk. SEBI Registration No. INH000013776.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Alembic_Pharmaceuticals_share_price_falling_in_2026\"><\/span><strong>Why is Alembic Pharmaceuticals share price falling in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Alembic Pharmaceuticals share price falling<\/strong> in 2026 is driven by broad market weakness from FII selling triggered by the US tariff announcement in April 2026, sector specific headwinds in the Generic Pharmaceuticals space, earnings growth deceleration, valuation de-rating from peak P\/E multiples, and small and mid cap segment liquidity headwinds. The <strong>Alembic Pharmaceuticals share price falling<\/strong> totals approximately 37 percent from the 52 week high of Rs 1,108 to the current Rs 700.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Alembic_Pharmaceuticals\"><\/span><strong>What is the 52 week high and low of Alembic Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52 week high of Alembic Pharmaceuticals is Rs 1,108 and the 52 week low is Rs 665. The current price of approximately Rs 700 represents a decline of about 37 percent from the 52 week high, classifying the <strong>Alembic Pharmaceuticals share price falling<\/strong> as a significant correction that requires careful investor analysis before any fresh position is taken.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_buy_Alembic_Pharmaceuticals_shares_at_current_levels\"><\/span><strong>Should I buy Alembic Pharmaceuticals shares at current levels?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Whether to buy Alembic Pharmaceuticals at Rs 700 during the <strong>Alembic Pharmaceuticals share price falling<\/strong> phase depends on your investment horizon, risk appetite, and your view on the company\u2019s fundamental recovery. The stock has fallen 37 percent from its peak, improving risk reward for patient investors with a 2 to 3 year view. However, near term volatility from the <strong>Alembic Pharmaceuticals share price falling<\/strong> trend may persist. Always consult a SEBI registered financial advisor before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_latest_news_affecting_Alembic_Pharmaceuticals_stock\"><\/span><strong>What is the latest news affecting Alembic Pharmaceuticals stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Recent developments adding to the <strong>Alembic Pharmaceuticals share price falling<\/strong> trend include the US 26 percent reciprocal tariff announcement that triggered FII selling, quarterly earnings showing pressure on margins and revenue growth, and sector level analyst estimate revisions across the Generic Pharmaceuticals space. Track the latest news and live data on Alembic Pharmaceuticals using the Univest Screener and research platform.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_recovery_triggers_for_Alembic_Pharmaceuticals\"><\/span><strong>What are the recovery triggers for Alembic Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key catalysts that could reverse the <strong>Alembic Pharmaceuticals share price falling<\/strong> trend include a quarterly earnings result that beats reduced analyst expectations, reversal of FII selling as global macro conditions improve post the tariff shock, positive sector re-rating in the Generic Pharmaceuticals space, and a broader small and mid cap market recovery in India. Any of these catalysts could arrest the <strong>Alembic Pharmaceuticals share price falling<\/strong> and trigger a sharp recovery from current levels.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_downside_risks_to_Alembic_Pharmaceuticals_stock\"><\/span><strong>What are the key downside risks to Alembic Pharmaceuticals stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The key risks that could extend the <strong>Alembic Pharmaceuticals share price falling<\/strong> phase include continued earnings estimate downgrades, further FII selling if global risk appetite remains negative, unexpected regulatory or competitive developments in the Generic Pharmaceuticals sector, and a deeper correction in the broader Indian small and mid cap equity segment. If these risks materialise together, the <strong>Alembic Pharmaceuticals share price falling<\/strong> trend could test the 52 week low support of Rs 665.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Why is Alembic Pharmaceuticals share price falling? Key reasons behind the decline from Rs 1,108 to Rs 700, financial analysis, and what investors should watch in 2026.<\/p>\n","protected":false},"author":26,"featured_media":87300,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-87163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778741308:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["78"],"rank_math_focus_keyword":["Alembic Pharmaceuticals Share Price Falling"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Why Is Alembic Pharmaceuticals Share Price Falling Key Reasons 2026"],"rank_math_description":["Why is Alembic Pharmaceuticals share price falling? Key reasons behind the decline from Rs 1,108 to Rs 700, financial analysis, and what investors should watch in 2026."],"_thumbnail_id":["87300"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11382"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/14121747\/Why-Is-Alembic-Pharmaceuticals-Share-Price-Falling-1.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=87163"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87163\/revisions"}],"predecessor-version":[{"id":87302,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87163\/revisions\/87302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/87300"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=87163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=87163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=87163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}